---
title: Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype
date: '2024-09-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39248309/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240909184358&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Depemokimab reduced the annualized rate of exacerbations
  among patients with severe asthma with an eosinophilic phenotype. (Funded by GSK;
  SWIFT-1 and SWIFT-2 ClinicalTrials.gov numbers, NCT04719832 and ...'
disable_comments: true
---
CONCLUSIONS: Depemokimab reduced the annualized rate of exacerbations among patients with severe asthma with an eosinophilic phenotype. (Funded by GSK; SWIFT-1 and SWIFT-2 ClinicalTrials.gov numbers, NCT04719832 and ...